Provided by Tiger Trade Technology Pte. Ltd.

Rafael Holdings, Inc.

2.16
-0.0800-3.57%
Post-market: 2.15-0.0100-0.46%19:06 EDT
Volume:315.57K
Turnover:701.79K
Market Cap:111.82M
PE:-3.17
High:2.33
Open:2.24
Low:2.09
Close:2.24
52wk High:2.65
52wk Low:1.12
Shares:51.77M
Float Shares:36.14M
Volume Ratio:0.55
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6807
EPS(LYR):-1.0373
ROE:-37.59%
ROA:-22.14%
PB:1.48
PE(LYR):-2.08

Loading ...

Israel expects new air defence orders from Europe due to Russia concerns

Reuters
·
Yesterday

IDT names William Conkling to board, taps him as audit committee chair

Reuters
·
Jun 12

Rafael Holdings Q3 EPS $(0.08) Up From $(0.19) YoY, Sales $179.000K Down From $362.000K YoY

Benzinga
·
Jun 11

Biotech firm Rafael's Q3 net loss narrows; set to submit NDA for Trappsol Cyclo in H2

Reuters
·
Jun 11

Rafael Holdings Q3 Net Income USD -2.899 Million

Reuters
·
Jun 11

Rafael Holdings FY26 Q3 net loss narrows to $4.2 million; revenue falls to $179,000

Reuters
·
Jun 11

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

THOMSON REUTERS
·
Jun 11

Rafael Holdings Q3 Operating Income USD -6.87 Million

THOMSON REUTERS
·
Jun 11

Rafael Holdings Q3 Revenue USD 89 Thousand

THOMSON REUTERS
·
Jun 11

Rafael Holdings completes Phase 3 TransportNPC trial of Trappsol Cyclo in Niemann-Pick type C

Reuters
·
Jun 10

Rafael - FDA Acknowledges US Expanded Access Program for Trappsol Cyclo Can Proceed

THOMSON REUTERS
·
Jun 10

Rafael - Expects Nda Submission for Trappsol Cyclo in Second Half of 2026

THOMSON REUTERS
·
Jun 10

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 Transportnpc™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

THOMSON REUTERS
·
Jun 10

BUZZ-U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj

Reuters
·
Jun 09

Rafael Holdings Announces Patent Licensing Agreement With Mit for “Small Molecules to Improve Myelination in Apoe4 Positive Alzheimer’s Disease”

THOMSON REUTERS
·
Apr 22

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

GlobeNewswire
·
Apr 22

Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs

Reuters
·
Mar 17

Rafael Holdings Q2 FY2026 R&D expenses more than tripled to USD 4.53 million as net loss attributable to shareholders widened 38.3% to USD 6.42 million

Reuters
·
Mar 17

BRIEF-Rafael Holdings Q2 Net Income USD -6.327 Million

Reuters
·
Mar 17

Rafael Holdings Q2 Revenue USD 125 Thousand

THOMSON REUTERS
·
Mar 17